Gilead Seladelpar Sustained Consistent Long-Term Efficacy and Safety in Primary Biliary Cholangitis

 

• Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis
• Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Participants with Moderate to Severe Symptoms
• Subset Analysis of Participants with Compensated Cirrhosis Demonstrated Clinically Meaningful Improvements in Markers of Cholestasis and Liver Injury

https://www.biospace.com/article/releases/gilead-s-seladelpar-demonstrated-a-sustained-and-consistent-long-term-efficacy-and-safety-profile-in-primary-biliary-cholangitis/